abstract |
In the present invention, it has been proven that molecules that interfere with the binding of a tumor necrosis factor receptor to its ligand, such as a soluble receptor, are useful in both basic research and therapy. The present invention provides improved soluble transmembrane activator and calcium modulator receptors and interacts with a cyclophilin ligand (TACI). |